| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.82 [0.72, 0.93] | | < 1 | | 0% | 2 studies (2/-) | 99.9 % | some concern | not evaluable | moderate | crucial | - |
| deaths (OS) (extension) | 0.74 [0.61, 0.90] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | important | - |
| progression or deaths (PFS) | 1.14 [0.82, 1.58] | | < 1 | | 85% | 2 studies (2/-) | 22.0 % | some concern | not evaluable | moderate | important | - |
| objective responses (ORR) | 0.73 [0.18, 2.99] | | > 1 | | 94% | 2 studies (2/-) | 33.3 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| AE (any grade) | 0.31 [0.22, 0.44] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| AE leading to death (grade 5) | 0.84 [0.48, 1.48] | | < 1 | | 0% | 1 study (1/-) | 72.6 % | NA | not evaluable | | non important | - |
| AE leading to treatment discontinuation (any grade) | 0.36 [0.23, 0.55] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 0.12 [0.02, 0.87] | | < 1 | | 96% | 2 studies (2/-) | 98.2 % | some concern | not evaluable | moderate | non important | - |
| TRAE (grade 3-4) | 0.15 [0.06, 0.39] | | < 1 | | 90% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to death (grade 5) | 0.75 [0.14, 3.93] | | < 1 | | 57% | 2 studies (2/-) | 63.1 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (any grade) | 1.20 [0.55, 2.62] | | < 1 | | 0% | 1 study (1/-) | 32.3 % | NA | not evaluable | | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 1.28 [0.53, 3.10] | | < 1 | | 0% | 1 study (1/-) | 29.1 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Acute kidney injury TRAE (grade 3-4) | 1.91 [0.06, 57.09] | | < 1 | | 0% | 1 study (1/-) | 35.7 % | NA | not evaluable | | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 1.42 [0.11, 18.53] | | < 1 | | 0% | 2 studies (2/-) | 39.6 % | some concern | not evaluable | moderate | non important | - |
| Alopecia TRAE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Anaemia TRAE (grade 3-4) | 0.05 [0.02, 0.17] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| Arthralgia TRAE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Asthenia TRAE (grade 3-4) | 0.19 [0.04, 0.88] | | < 1 | | 0% | 2 studies (2/-) | 98.3 % | some concern | not evaluable | moderate | non important | - |
| Blood and lymphatic system disorders TRAE (grade 3-4) | 0.03 [0.01, 0.07] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| Blood creatinine increased TRAE (grade 3-4) | 0.95 [0.06, 15.29] | | < 1 | | 0% | 2 studies (2/-) | 51.3 % | some concern | not evaluable | moderate | non important | - |
| Cardiac disorders TRAE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Chills TRAE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 0.96 [0.16, 5.54] | | < 1 | | 0% | 2 studies (2/-) | 52.0 % | some concern | not evaluable | moderate | non important | - |
| Constipation TRAE (grade 3-4) | 0.64 [0.05, 8.37] | | < 1 | | 0% | 2 studies (2/-) | 63.2 % | some concern | not evaluable | moderate | non important | - |
| Cough TRAE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.34 [0.02, 4.81] | | < 1 | | 47% | 2 studies (2/-) | 78.7 % | some concern | not evaluable | moderate | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.85 [0.04, 16.24] | | < 1 | | 73% | 2 studies (2/-) | 54.4 % | some concern | not evaluable | moderate | non important | - |
| Dyspepsia TRAE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Dyspnoea TRAE (grade 3-4) | 3.83 [0.17, 85.33] | | < 1 | | 0% | 1 study (1/-) | 20.1 % | NA | not evaluable | | non important | - |
| Endocrine disorders TRAE (grade 3-4) | 3.56 [0.38, 33.73] | | < 1 | | 0% | 2 studies (2/-) | 13.6 % | some concern | not evaluable | moderate | non important | - |
| Epistaxis TRAE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Eye disorders TRAE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 0.64 [0.09, 4.64] | | < 1 | | 71% | 2 studies (2/-) | 66.8 % | some concern | not evaluable | moderate | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 0.05 [0.00, 0.79] | | < 1 | | 0% | 1 study (1/-) | 98.2 % | NA | not evaluable | | non important | - |
| Gastritis TRAE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Gastrointestinal disorders TRAE (grade 3-4) | 0.17 [0.03, 0.80] | | < 1 | | 78% | 2 studies (2/-) | 98.7 % | some concern | not evaluable | moderate | non important | - |
| General disorders and administration site conditions TRAE (grade 3-4) | 0.33 [0.11, 0.97] | | < 1 | | 66% | 2 studies (2/-) | 97.8 % | some concern | not evaluable | moderate | non important | - |
| Guillain-Barré syndrome TRAE (grade 3-4) | 1.91 [0.06, 57.09] | | < 1 | | 0% | 1 study (1/-) | 35.7 % | NA | not evaluable | | non important | - |
| Headache TRAE (grade 3-4) | 0.47 [0.02, 14.21] | | < 1 | | 0% | 1 study (1/-) | 66.4 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 2.86 [0.29, 28.34] | | < 1 | | 0% | 2 studies (2/-) | 18.6 % | some concern | not evaluable | moderate | non important | - |
| Hepatobiliary disorders TRAE (grade 3-4) | 0.95 [0.06, 15.29] | | < 1 | | 0% | 1 study (1/-) | 51.4 % | NA | not evaluable | | non important | - |
| Hypersensitivity TRAE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Hypertension TRAE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.42 [0.11, 18.53] | | < 1 | | 0% | 2 studies (2/-) | 39.6 % | some concern | not evaluable | moderate | non important | - |
| Hypophysitis TRAE (grade 3-4) | 1.92 [0.06, 57.35] | | < 1 | | 0% | 1 study (1/-) | 35.6 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 1.91 [0.06, 57.09] | | < 1 | | 0% | 1 study (1/-) | 35.7 % | NA | not evaluable | | non important | - |
| Increase AST TRAE (grade 3-4) | 0.31 [0.03, 3.04] | | < 1 | | 0% | 1 study (1/-) | 84.0 % | NA | not evaluable | | non important | - |
| Increased ALT TRAE (grade 3-4) | 0.16 [0.01, 3.15] | | < 1 | | 0% | 1 study (1/-) | 88.4 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 0.37 [0.08, 1.63] | | < 1 | | 0% | 2 studies (2/-) | 90.5 % | some concern | not evaluable | moderate | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.04 [0.01, 0.32] | | < 1 | | 0% | 2 studies (2/-) | 99.9 % | some concern | not evaluable | moderate | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 0.47 [0.02, 14.21] | | < 1 | | 0% | 1 study (1/-) | 66.4 % | NA | not evaluable | | non important | - |
| Metabolism and nutrition disorders TRAE (grade 3-4) | 0.28 [0.16, 0.50] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| Mucosal inflammation TRAE (grade 3-4) | 0.15 [0.04, 0.50] | | < 1 | | 0% | 2 studies (2/-) | 99.9 % | some concern | not evaluable | moderate | non important | - |
| Musculoskeletal and connective tissue disorders TRAE (grade 3-4) | 1.91 [0.06, 57.09] | | < 1 | | 0% | 1 study (1/-) | 35.7 % | NA | not evaluable | | non important | - |
| Myalgia TRAE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Myocarditis TRAE (grade 3-4) | 0.96 [0.02, 48.37] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
| Myositis TRAE (grade 3-4) | 0.48 [0.02, 14.29] | | < 1 | | 0% | 1 study (1/-) | 66.3 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 0.10 [0.01, 1.53] | | < 1 | | 36% | 2 studies (2/-) | 95.0 % | some concern | not evaluable | moderate | non important | - |
| Nephritis TRAE (grade 3-4) | 3.85 [0.17, 85.65] | | < 1 | | 0% | 1 study (1/-) | 20.0 % | NA | not evaluable | | non important | - |
| Nervous system disorders TRAE (grade 3-4) | 0.47 [0.04, 5.26] | | < 1 | | 0% | 1 study (1/-) | 72.7 % | NA | not evaluable | | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.02 [0.00, 0.13] | | < 1 | | 14% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Pancreatitis TRAE (grade 3-4) | 0.96 [0.02, 48.37] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
| Pancytopenia TRAE (grade 3-4) | 0.16 [0.01, 3.15] | | < 1 | | 0% | 1 study (1/-) | 88.4 % | NA | not evaluable | | non important | - |
| Paraesthesia TRAE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Peripheral oedema TRAE (grade 3-4) | 1.91 [0.06, 57.09] | | < 1 | | 0% | 1 study (1/-) | 35.7 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 1.89 [0.46, 7.82] | | < 1 | | 0% | 2 studies (2/-) | 18.9 % | some concern | not evaluable | moderate | non important | - |
| Pruritic rash TRAE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Pruritus generalised TRAE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 0.24 [0.01, 5.27] | | < 1 | | 0% | 1 study (1/-) | 81.6 % | NA | not evaluable | | non important | - |
| Pyrexia TRAE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 0.23 [0.03, 1.77] | | < 1 | | 46% | 2 studies (2/-) | 92.0 % | some concern | not evaluable | moderate | non important | - |
| Renal and urinary disorders TRAE (grade 3-4) | 1.91 [0.06, 57.09] | | < 1 | | 0% | 1 study (1/-) | 35.7 % | NA | not evaluable | | non important | - |
| Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) | 1.44 [0.40, 5.16] | | < 1 | | 0% | 1 study (1/-) | 28.9 % | NA | not evaluable | | non important | - |
| Sepsis TRAE (grade 3-4) | 0.24 [0.01, 5.27] | | < 1 | | 0% | 1 study (1/-) | 81.6 % | NA | not evaluable | | non important | - |
| Severe skin reaction TRAE (grade 3-4) | 0.36 [0.17, 0.76] | | < 1 | | 0% | 2 studies (2/-) | 99.6 % | some concern | not evaluable | moderate | non important | - |
| Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 0.31 [0.08, 1.15] | | < 1 | | 0% | 1 study (1/-) | 95.9 % | NA | not evaluable | | non important | - |
| Skin exfoliation TRAE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Stevens-Johnson syndrome TRAE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Stomatitis TRAE (grade 3-4) | 0.07 [0.01, 0.36] | | < 1 | | 0% | 2 studies (2/-) | 99.9 % | some concern | not evaluable | moderate | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.05 [0.01, 0.26] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| Thyroiditis TRAE (grade 3-4) | 0.96 [0.02, 48.37] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
| Uveitis TRAE (grade 3-4) | 0.96 [0.02, 48.37] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
| Vascular disorders TRAE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 0.09 [0.01, 1.73] | | < 1 | | 0% | 1 study (1/-) | 94.2 % | NA | not evaluable | | non important | - |
| Weight decreased TRAE (grade 3-4) | 0.95 [0.10, 9.21] | | < 1 | | 0% | 2 studies (2/-) | 51.6 % | some concern | not evaluable | moderate | non important | - |
AE (grade 3-4) endpoints 00 |
| Abdominal pain AE (grade 3-4) | 0.19 [0.02, 1.62] | | < 1 | | 0% | 1 study (1/-) | 93.4 % | NA | not evaluable | | non important | - |
| Acute kidney injury AE (grade 3-4) | 1.93 [0.35, 10.60] | | < 1 | | 0% | 1 study (1/-) | 22.7 % | NA | not evaluable | | non important | - |
| Anaemia AE (grade 3-4) | 0.24 [0.13, 0.44] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Asthenia AE (grade 3-4) | 0.31 [0.08, 1.16] | | < 1 | | 0% | 1 study (1/-) | 95.8 % | NA | not evaluable | | non important | - |
| Back pain AE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Blood and lymphatic system disorders AE (grade 3-4) | 0.10 [0.06, 0.18] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Decreased appetite AE (grade 3-4) | 0.28 [0.08, 1.03] | | < 1 | | 0% | 1 study (1/-) | 97.2 % | NA | not evaluable | | non important | - |
| Diarrhoea AE (grade 3-4) | 0.23 [0.05, 1.11] | | < 1 | | 0% | 1 study (1/-) | 96.6 % | NA | not evaluable | | non important | - |
| Dizziness AE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Dyspnoea AE (grade 3-4) | 2.26 [0.58, 8.83] | | < 1 | | 0% | 1 study (1/-) | 12.1 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 0.60 [0.26, 1.42] | | < 1 | | 0% | 1 study (1/-) | 87.7 % | NA | not evaluable | | non important | - |
| Febrile neutropenia AE (grade 3-4) | 0.03 [0.00, 0.47] | | < 1 | | 0% | 1 study (1/-) | 99.3 % | NA | not evaluable | | non important | - |
| Gastrointestinal disorders AE (grade 3-4) | 0.33 [0.20, 0.56] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
